Drug intelligence / Profile preview

Lixelle

Development stage: Unknown
Lead developer: Kaneka
Administration: Percutaneous

Overview

Lixelle is a selective beta-2 microglobulin (β2-MG) adsorption column developed by Kaneka Corporation for the treatment of dialysis-related amyloidosis (DRA). It consists of porous cellulose beads covalently bonded with a hexadecyl group, which acts as a hydrophobic ligand to specifically capture β2-MG from the blood during extracorporeal circulation. By reducing systemic levels of β2-MG—the precursor protein for amyloid fibrils—Lixelle aims to prevent or slow the progression of DRA-associated complications, such as carpal tunnel syndrome, bone cysts, and destructive spondyloarthropathy. It is typically used in series with a conventional hemodialyzer during hemodialysis or hemodiafiltration sessions.

Brand names: Lixelle
Other names: beta2-microglobulin adsorption columnbeta-2-microglobulin adsorption columnbeta 2-microglobulin adsorption column

Beyond the preview

Go deeper on Lixelle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lixelle.

Explore the full profile